PATENT CLAIM ANALYSIS

Application Number: 15991326
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.

Claim (Index 14):
An oligonucleotide comprising or consisting of an oligonucleotide selected from the group consisting of: (SEQ ID NO 67.1) T s T s m C s t s a s t s c s t s a s m c s g s c s a s T s T s G,   (SEQ ID NO 73.1) m C s T s T s m C s t s t s c s t s a s t s c s t s a s m c s g s c s A s T, and   (SEQ ID NO 86.1) T s A s m C s T s t s t s a s a s t s a s g s c s T s m C s A s A; wherein capital letters represent beta-D-oxy LNA nucleosides, lower case letters are DNA nucleosides, subscript s represents a phosphorothioate internucleoside linkage, and  m C represent 5 methyl cytosine beta-D-oxy LNA nucleosides, and  m c represents 5 methyl cytosine DNA nucleosides.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15635629', '15971951', '14897223', '15971970', '15836144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7585167453499653
- 35 USC 102 Novelty (BERT): 0.6019118363209579
- Combined Prediction Score: 0.7428562544470645
- Mean Citation Score: 424.386488
- Max Citation Score: 602.95087
- Similarity Product: 423.7639556549764

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test